Cara Therapeutics Inc (NASDAQ:CARA)’s traded shares stood at 0.57 million during the last session, with the company’s beta value hitting 0.68. At the close of trading, the stock’s price was $0.27, to imply a decrease of -1.23% or $0.0 in intraday trading. The CARA share’s 52-week high remains $1.31, putting it -385.19% down since that peak but still an impressive 11.11% since price per share fell to its 52-week low of $0.24. The company has a valuation of $14.59M, with an average of 0.42 million shares in intraday trading volume over the past 10 days and average of 532.99K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cara Therapeutics Inc (CARA), translating to a mean rating of 2.60. Of 4 analyst(s) looking at the stock, 1 analyst(s) give CARA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cara Therapeutics Inc (NASDAQ:CARA) trade information
After registering a -1.23% downside in the last session, Cara Therapeutics Inc (CARA) has traded red over the past five days. The 5-day price performance for the stock is -12.50%, and -14.55% over 30 days. With these gigs, the year-to-date price performance is -64.20%. Short interest in Cara Therapeutics Inc (NASDAQ:CARA) saw shorts transact 0.94 million shares and set a 2.2 days time to cover.
The extremes give us $1 and $1 for target low and target high price respectively. As such, CARA has been trading -270.37% off suggested target high and -270.37% from its likely low.
Cara Therapeutics Inc (CARA) estimates and forecasts
Looking at statistics comparing Cara Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Cara Therapeutics Inc (CARA) shares are -57.39% down over the last 6 months, with its year-to-date growth rate higher than industry average at 43.38% against 17.50%. The rating firms project that company’s revenue will shrink -68.41% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 1.6M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 1.2M.Earnings reports from the last fiscal year show that sales brought in 3M and 2.13M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -46.87% before dropping -43.79% in the following quarter.
CARA Dividends
Cara Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cara Therapeutics Inc (NASDAQ:CARA)’s Major holders
Cara Therapeutics Inc insiders hold 15.74% of total outstanding shares, with institutional holders owning 28.16% of the shares at 33.42% float percentage. In total, 28.16% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 2.25 million shares (or 4.1224% of shares), all amounting to roughly $0.58 million.
The next major institution holding the largest number of shares is DISCIPLINED GROWTH INVESTORS INC /MN with 1.94 million shares, or about 3.546% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.5 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Cara Therapeutics Inc (CARA) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 1.35 shares. This is just over 2.47% of the total shares, with a market valuation of $0.36 million. Data from the same date shows that the other fund manager holds a little less at 645.75, or 1.18% of the shares, all valued at about 0.17 million.
